AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05957055
Drug: Lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
Trial: NCT05957055
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
Trial: NCT06166602
Drug: PENG block with 0.25% bupivacaine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
Trial: NCT00730444
Drug: Iobenguane I 123 Injection
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-10 mCi administered intravenously
Trial: NCT05375747
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
Trial: NCT05375747
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
Trial: NCT00686478
Drug: interferon alpha 2b
RxNorm normalized name: PEGINTERFERON ALPHA 2B 80MCG/0.5ML INJ,KIT
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
Trial: NCT06374771
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gm of Vitamin C will be given orally pre and post-operative
Trial: NCT05237297
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10mg
Trial: NCT05237297
Drug: Aceclofenac
RxNorm normalized name: Aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100mg
Trial: NCT03424473
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04542304
Drug: Metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given a metolazone for the 1-week study period.
Trial: NCT04906902
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet taken by mouth twice daily
Trial: NCT04963231
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SC injection
Trial: NCT06569251
Drug: Dexamethasone 12 mg QD
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
Trial: NCT06569251
Drug: Dexamethasone 6 mg BID
RxNorm normalized name: dexamethasone 6 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
Trial: NCT05860933
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05860933
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06483672
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib 80mg, once daily, orally
Trial: NCT06483672
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
Trial: NCT05622370
Drug: Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)
RxNorm normalized name: brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.
Trial: NCT05622370
Drug: Brivaracetam sustained-release tablets 100mg
RxNorm normalized name: brivaracetam Oral Tablet
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Trial: NCT05691478
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05691478
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05622370
Drug: Brivaracetam sustained-release tablets 50mg
RxNorm normalized name: brivaracetam Oral Tablet
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Trial: NCT03205137
Drug: Subjects treated with Telmisartan and amlodipine
RxNorm normalized name: telmisartan and amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects treated with Telmisartan and amlodipine
Trial: NCT03205137
Drug: subjects treated with telmisartan+amlodipine double pill
RxNorm normalized name: amlodipine / telmisartan Pill
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects treated with telmisartan+amlodipine double pill
Trial: NCT05324618
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
Trial: NCT06103188
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam will be given to the patients 1 hour prior to their planned surgery.
Trial: NCT06274008
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
Trial: NCT04558281
Drug: Active ropivacaine 0.3% erector spinae plane perineural administration
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
Trial: NCT06479759
Drug: LM-108 antibody and sintilimab
RxNorm normalized name: acetaminophen
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
Trial: NCT06479759
Drug: LM-108 antibody and sintilimab and chemotherapy
RxNorm normalized name: acetaminophen
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
Trial: NCT01249105
Drug: MK-2206
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a week
Trial: NCT06195683
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
Trial: NCT05238506
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous lidocaine infusion.
Trial: NCT05238506
Drug: Normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous normal saline infusion.
Trial: NCT05860335
Drug: Cisplatin/Nedaplatin, albumin paclitaxel
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
Trial: NCT05300932
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally take Baricitinib 4mg everyday for 48 weeks
Trial: NCT05659056
Drug: Pyrotinib, trastuzumab, paclitaxel-albumin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
Trial: NCT05806723
Drug: Atorvastatin 40 Mg Oral Tablet
RxNorm normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily drug intake during six months
Trial: NCT06344442
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
Trial: NCT05560035
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
Trial: NCT04313972
Drug: low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
Trial: NCT05557838
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (intravenous infusion)
Trial: NCT05557838
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab IV (intravenous infusion)
Trial: NCT05827614
Drug: BBI-355
RxNorm normalized name: BBIBP-CorV
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CHK1 inhibitor
Trial: NCT05827614
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR Inhibitor
Trial: NCT05827614
Drug: Futibatinib
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGFR1-4 Inhibitor
Trial: NCT06195514
Drug: TAK-113
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Description: TAK-113 5 mg capsules, orally, once daily, in a 3 weeks on/1 week off schedule for each 4-week cycle per treatment guidelines.
Trial: NCT05517993
Drug: Gui-Lu-Er-Xian-Jiao-Wan
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
Trial: NCT05805930
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: : Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
Trial: NCT05805930
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
Trial: NCT00359697
Drug: Hypertonic Saline, Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06258330
Drug: AM003
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bispecific Personalized Aptamer for intratumoral administration
Trial: NCT05112991
Drug: Envafolimab+Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle.
Trial: NCT05112991
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
Trial: NCT06572241
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
Trial: NCT05951517
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF treat refractory gastrointestinal Henoch-Schönlein purpura
Trial: NCT04809779
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
Trial: NCT06468215
Drug: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
Trial: NCT05353985
Drug: TAK-062
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-062 tablets.
Trial: NCT04894994
Drug: FLX475
RxNorm normalized name: FLX475
DrugBank: FLX475 (DB15570)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04894994
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT06684106
Drug: Ursodeoxycholic acid (UDCA) 500 mg
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA together with statin in eligible participants
Trial: NCT06709885
Drug: Chidamide + Tislelizumab + chemotherapy (CapeOX )
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox
Trial: NCT06527729
Drug: sildenafil-loaded liposomes
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
Trial: NCT06527729
Drug: minoxidil gel
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
Trial: NCT06709092
Drug: lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)
RxNorm normalized name: fumarate
DrugBank: Calcium monoethylfumarate (DB15816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
Trial: NCT05463848
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05463848
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pill taken by mouth
Trial: NCT05463848
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pill taken by mouth
Trial: NCT06707181
Drug: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
Trial: NCT04765111
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05785611
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally once daily
Trial: NCT04778046
Drug: Hyperpolarized 129Xe
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
Trial: NCT06516484
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
Trial: NCT05351801
Drug: THC (Syndros)
RxNorm normalized name: Syndros
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a target dose of 10mg per day of THC (Syndros).
Trial: NCT05351801
Drug: CBD (Epidolex)
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
Trial: NCT05351801
Drug: THC + CBD (Nabiximols)
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).